Impact of natural killer cells on chronic hepatitis C and hepatocellular carcinoma

Hepatology Research

Volumn 46, Issue 5, 2016, Pages 416-422

  Tatsumi, Tomohide ^a   Takehara, Tetsuo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis C; DAA; Hepatocellular carcinoma; Innate immunity; Interferon; NK cells

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D;

ACUTE HEPATITIS C; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHRONIC HEPATITIS C; CYTOKINE PRODUCTION; HUMAN; LIVER CELL CARCINOMA; LYMPHOCYTE DIFFERENTIATION; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; VIRAL CLEARANCE; VIRUS INHIBITION;

EID: 84957998956     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12619     Document Type: Review

References (74)

1. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol 2006; 41: 17-27.
2. Mishra P, Murray J, Birnkrant D. Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs. Hepatology 2015; 62: 1298-303.
3. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001; 1: 41-9.
4. Doherty DG, O'Farrelly C. Innate and adaptive lymphoid cells in human liver. Immunol Rev 2000; 174: 5-20.
5. Lunemann S, Schlaphoff V, Cornberg M, Wedemeyer H. NK cells in hepatitis C: Role in disease susceptibility and therapy. Dig Dis 2012; 30: 48-54.
6. Saha B, Szabo G. Innate immune cell networking in hepatitis C virus infection. J Leukoc Biol 2014; 96: 757-66.
7. Golden-Mason L, Rosen HR. Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol Rev 2013; 255: 68-81 (in press 2015).
8. Llano M, Guma M, Ortega M, Angulo A, Lopez-Botet M. Differential effects of US2, US6 and US11 human cytomegalovirus proteins on HLA class Ia and HLA-E expression: impact on target susceptibility to NK cell subsets. Eur J Immunol 2003; 33: 2744-54.
9. Vidal SM, Khakoo SI, Biron CA. Natural killer cell responses during viral infections: flexibility and conditioning of innate immunity by experience. Curr Opin Virol 2011; 1: 497-512.
10. Grégoire C, Chesson L, Luci C, et al. The trafficking of natural killer cells. Immunol Rev 2007; 220: 169-82.
11. Watzl C, Long EO. Signal transduction during activation and inhibition of natural killer cells. Curr Protoc Immunol 2010; 11: Unit 11.9B.
12. Parham P. Influence of KIR diversity on human immunity. Adv Exp Med Biol 2005; 560: 47-50.
13. Burgess SJ, Maasho K, Masilamani M, Narayanan S, Borrego F, Coligan JE. The NKG2D receptor: immunobiology and clinical implications. Immunol Res 2008; 40: 18-34.
14. Koch J, Steinle A, Watzl C, Mandelboim O. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol 2013; 34: 182-91.
15. Pogge von Strandmann E, Simhadri VR, von Tresckow B, et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007; 27: 965-74.
16. Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, Mandelboim O. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 2001; 31: 2680-9.
17. Jarahian M, Watzl C, Fournier P, et al. Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol 2009; 83: 8108-21.
18. Mandelboim O, Lieberman N, Lev M, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001; 409: 1055-60.
19. Ahlenstiel G. The natural killer cell response to HCV infection. Immune Net 2013; 13: 168-76.
20. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305: 872-4.
21. Golden-Mason L, Cox AL, Randall JA, Cheng L, Rosen HR. Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology 2010; 52: 1581-9.
22. Werner JM, Heller T, Gordon AM, et al. Innate immune responses in hepatitis C virus exposed healthcare workers who do not develop acute infection. Hepatology 2013; 58: 1621-31.
23. Amadei B, Urbani S, Cazaly A, et al. Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology 2010; 138: 1536-45.
24. Alter G, Jost S, Rihn S, et al. Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance. J Hepatol 2011; 55: 278-88.
25. Morishima C, Paschal DM, Wang CC, et al. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology 2006; 43: 573-80.
26. Bonorino P, Ramzan M, Camous X, et al. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol 2009; 51: 458-67.
27. Golden-Mason L, Madrigat-Estebas L, McGrath E, et al. Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut 2008; 57: 1121-8.
28. Gonzalez VD, Falconer K, Björkström NK, et al. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment. J Immunol 2009; 183: 6612-8.
29. Jinushi M, Tekehara T, Tatsumi T, et al. Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol 2004; 173: 6072-81.
30. de Maria A, Fogli M, Mazza S, et al. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol 2007; 37: 445-55.
31. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer cell subsets. Trends Immunol 2001; 22: 633-40.
32. Ahlenstiel G, Titerence RH, Koh C et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 2010; 138: 325-35. e1-2.
33. Jinushi M, Takehara T, Kanto T, et al. Critical role of MICA/B expression on interferon α-stimulated dendritic cells in natural killer cell activation: Impairment in chronic hepatitis C virus infection. J Immunol 2003; 170: 1249-56.
34. Sène D, Levasseur F, Abel M, et al. Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines. PLoS Pathog 2010; 6: e1001184.
35. Yoon JC, Lim JB, Park JH, Lee JM. Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells. J Virol 2011; 85: 12557-69.
36. Nattermann J, Feldmann G, Ahlenstiel G, Langhans B, Sauerbruch T, Spengler U. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 2006; 55: 869-77.
37. Harrison RJ, Ettorre A, Little AM, Khakoo SI. Association of NKG2A with treatment for chronic hepatitis C virus infection. Clin Exp Immunol 2010; 161: 306-14.
38. Kramer BC, Korner M, Kebschull A, et al. Natural killer p46High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis. Hepatology 2010; 56: 1201-3.
39. Pembroke T, Christian A, Jones E, et al. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus- induced pathology but in-vivo resistance to interferon alpha treatment. Gut 2014; 63: 515-24.
40. Oliviero B, Varchetta S, Paudice E et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009; 137: 1151-60, 1160 e1-7.
41. Mondelli MU, Oliviero B, Mele D, Mantovani S, Gazzabin C, Varchetta S. Natural killer cell functional dichotomy: a feature of chronic viral hepatitis? Front Immunol 2012; 3: 351.
42. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997; 15: 749-95.
43. Wang SH, Huang CX, Ye L, et al. Natural killer cells suppress full cycle HCV infection of human hepatocytes. J Viral Hepat 2008; 15: 855-64.
44. Crotta S, Brazzoli M, Piccioli D, Valiante NM, Wack A. Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection. J Hepatol 2010; 52: 183-90.
45. Serti E, Werner JM, Chattergoon M, Cox AL, Lohmann V, Rehermann B. Monocytes activates natural killer cells via inflammasome-induced interleukin 18 in response to hepatitis C virus replication. Gastroenterology 2014; 147: 209-20.
46. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 2015; 62(1 Suppl): S87-99.
47. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999; 17: 189-220.
48. Stegmann KA, Björkström NK, Ciesek S, et al. Interferon α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. J Infect Dis 2012; 205: 1351-62.
49. Stegmann KA, Björkström NK, Veber H, et al. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 2010; 138: 1885-97.
50. Ahlenstiel G, Edlich B, Hogdal LJ, et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 2011; 141: 1231-9.
51. Oliviero B, Mele D, Degasperi E, et al. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. J Hepatol 2013; 59: 38-44.
52. Bozzano F, Picciotto A, Costa P, et al. Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. Eur J Immunol 2011; 41: 2905-14.
53. Golden-Mason L, Bambha KM, Cheng L, et al. Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology 2011; 54: 1559-69.
54. Spaan M, van Oord G, Kreefft K et al. Immunological analysis during IFN-free therapy for chronic HCV reveals modulation of the NK cell compartment. J Infect Dis (in press 2015)
55. Serti E, Chepa-Lotera X, Kim YJ, et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 2015; 149: 190-200.
56. Guerra N, Tan YX, Joncker NT, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28: 571-80.
57. Cai L, Zhang Z, Zhou L, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 2008; 129: 428-37.
58. Wu Y, Kuang DM, Pan WD, et al. Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. Hepatology 2013; 57: 1107-16.
59. Groh V, Wu J, Yee C, Spies T. Tumor-derived soluble MIC ligands impair expression of NKG2D and T cell activation. Nature 2002; 419: 734-8.
60. Jinushi M, Takehara T, Tatsumi T, et al. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 2005; 43: 1013-20.
61. Tian Z, Chen Y, Gao B. Natural killer cells in liver disease. Hepatology 2013; 57: 1654-62.
62. Sun C, Sun H, Xiao W, Zhang C, Tian Z. Natural killer dysfunction in hepatocelluar carcinoma and NK cell-based immunotherapy. Acta Pharmacol Sin 2015; 36: 1191-9.
63. Tatsumi T, Takehara T, Yamaguchi S, et al. Intrahepatic delivery of α-galactosylceramide-pulsed dendritic cells suppresses liver tumor. Hepatology 2007; 45: 22-30.
64. Barajas M, Mazzolini G, Genove G, et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 2001; 33: 52-61.
65. Tatsumi T, Takehara T, Yamaguchi S, et al. Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity. Gene Ther 2007; 14: 863-71.
66. Jiang W, Zhang C, Tian Z, Zhang J. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo. Immunobiology 2014; 219: 547-53.
67. Jiang W, Zhang C, Tian Z, Zhang J. hIFN-alpha gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function. Gene Ther 2013; 20: 1062-9.
68. Kumar V, Kato N, Urabe Y, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 2011; 43: 455-8.
69. Ogasawara K, Lanier LL. NKG2D in NK and T cell-mediated immunity. J Clin Immunol 2005; 25: 534-40.
70. Jinushi M, Takehara T, Tatsumi T, et al. Expression of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acids. Int J Cancer 2003; 104: 354-61.
71. Kohga K, Takehara T, Tatsumi T, et al. Anticancer chemotherapy inhibits MHC Class I-related chain A ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Cancer Res 2009; 69: 8050-7.
72. Kohga K, Takehara T, Tatsumi T et al. Sorafenib inhibits the shedding of major histocomaptibility complex class I-related chain A on hepatocellular cacrcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology 51: 1264-73.
73. Sprinzl MF, Reisinger F, Puschnik A, et al. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology 2013; 57: 2358-68.
74. Armeanu S, Krusch M, Baltz KM, et al. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res 2008; 14: 3520-8.